Zealand Pharma

This study is following children with congenital hyperinsulinism (CHI) to see how safe and effective the drug dasiglucagon is over a long period. CHI causes dangerously low blood sugar. The drug is given as a continuous infusion under the skin. The main goal is to monitor side ef…

This early-stage study is testing a potential weight management drug called petrelintide. It aims to see if using different concentrations of the same single injection dose changes how the body absorbs and handles the drug, and if it affects safety. The study involves 48 adults w…

This study is a two-year follow-up to check the long-term safety and continued effectiveness of a weekly injection called glepaglutide for adults with short bowel syndrome (SBS). It includes 129 participants who have already completed a previous trial. The main goal is to monitor…

This study is testing the long-term safety and effectiveness of a drug called glepaglutide for people with short bowel syndrome. The trial involves 145 patients who previously participated in related studies, following them to see if the treatment continues to help reduce their n…

This study follows patients with short bowel syndrome for two years to see if continuing treatment with glepaglutide remains safe and effective. It includes 35 adults who were already receiving this medication in previous trials. The main goal is to monitor side effects and see i…

This study is testing a new weekly injection called petrelintide to see if it helps people with obesity and type 2 diabetes lose weight and better control their blood sugar. About 221 participants will receive either the drug or a placebo (dummy injection) for comparison. The mai…